What is the current stock price of AstraZeneca PLC (AZN)?

As of the latest market data, AstraZeneca PLC (AZN) is trading at $188.26. The stock has seen a gain of 0.43% today.

Does AstraZeneca PLC (AZN) pay a dividend?

Based on current data, AstraZeneca PLC does not have a confirmed active dividend policy.

What is the market cap of AstraZeneca PLC?

The current market capitalization of AstraZeneca PLC (AZN) is approximately unavailable.

AZN

AstraZeneca PLC·Healthcare

188.26

0.427%(+0.80)

Market Open

Last Updated: — ET

52W L: $137.2252W H: $212.71

AZN NEWS

fool.com

2d ago

3 International ETFs for Investors Looking Beyond U.S. Stocks

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

zacks.com

3d ago

AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings

AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.

zacks.com

3d ago

AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy

AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

zacks.com

3d ago

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

gurufocus.com

3d ago

AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug

AstraZeneca (AZN) has won US FDA approval for Baxfendy, giving the drugmaker a potentially important new growth lever as it aims to generate more than $5 billio

247wallst.com

3d ago

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

94,300

IPO Date

1993-05-12

Beta

0.22

Websitewww.astrazeneca.com↗